Document is current

Article History

Received: 18 August 2020

Accepted: 2 February 2021

First Online: 1 March 2021

Ethics approval and consent to participate {24}

: The study will be carried out in accordance with the current version of the Declaration of Helsinki and approved by the Ethics Committee of the Canton of Bern, Switzerland (KEK-Nr. 2020-00039). Written, informed consent to participate will be obtained from all participants. If the participant is unable to provide consent, their family members, an authorized representative, or a neutral physician may provide consent until the participant is able to do so.

: Not applicable.

: The Department of Intensive Care Medicine has, or has had in the past, research and development/consulting contracts with Edwards Lifesciences Services GmbH, Phagenesis Limited, and Nestlé. The money was paid into a departmental fund, and none of the authors received any financial gain. The Department of Intensive Care Medicine has received in the past unrestricted educational grants from the following organizations for organizing bi-annual postgraduate courses in the fields of critical care ultrasound, management of ECMO, and mechanical ventilation: Pierre Fabre Pharma AG (formerly known as RobaPharm), Pfizer AG, Bard Medica S.A., Abbott AG, Anandic Medical Systems, PanGas AG Healthcare, Orion Pharma, Bracco, Edwards Lifesciences AG, Hamilton Medical AG, Fresenius Kabi (Schweiz) AG, Getinge Group Maquet AG, Dräger Schweiz AG, and Teleflex Medical GmbH.None of the authors has any personal conflicts of interest to disclose.